• Malaria and the Historic RTS,S Vaccine

  • Jul 6 2022
  • Length: 22 mins
  • Podcast

Malaria and the Historic RTS,S Vaccine

Listen for free

View show details

  • Summary

  • https://www.metaculus.com/notebooks/10685/malaria-and-the-historic-rtss-vaccine/

    The following essay was contributed by public health researcher Jon Servello.

     

    This essay makes extensive use of abbreviations. The list can be found here.

    Malaria caused 627,000 deaths in 2020, largely among children under five years of age in sub-Saharan Africa. Interventions aimed at preventative treatment could save a considerable number of lives, bring about long-term economic benefits to countries with endemic malaria, and yield substantial benefits to humanity as a whole. 

    After decades of varied success in vaccine development, a four-dose regimen of RTS,S/AS01 (brand name Mosquirix) showed promising initial results in preventing clinical disease from Plasmodium falciparum at 11 trial sites across west and central Africa, though this quickly declined to an average of 25.9% efficacy in the 6 to 12 week old age range, and 36.3% in the 5 to 17 month range. The European Medicines Agency licensed the vaccine in 2015, and RTS,S/AS01 is being rolled out via the Malaria Vaccine Implementation Program (MVIP) by the World Health Organization in Ghana, Malawi, and Kenya.
    Show More Show Less
Show More Show Less

What listeners say about Malaria and the Historic RTS,S Vaccine

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.